High doses of pergolide improve clinical global impression in advanced Parkinson's disease - A preliminary open label study

Archives of Gerontology and Geriatrics

Volumn 41, Issue 3, 2005, Pages 239-253

  Arnold, Guy ^a   Gasser, Thomas ^b,f   Storch, Alexander ^c,g   Lipp, Axel ^a   Kupsch, Andreas ^a   Hundemer, Hans Peter ^d   Schwarz, Johannes ^c,e  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c UNIVERSITY OF ULM   (Germany)

^d LILLY DEUTSCHLAND GMBH   (Germany)

^e UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^f UNIVERSITY OF TÜBINGEN   (Germany)

^g UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

Author keywords

Adverse events; Dopamine agonist; Dyskinesias; Levodopa related motor fluctuations; Parkinson's disease

Indexed keywords

LEVODOPA; PERGOLIDE;

ABDOMINAL PAIN; ADULT; AGED; ANXIETY; ARTICLE; ASTHENIA; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; FEMALE; HALLUCINATION; HUMAN; MALE; PARKINSON DISEASE; PERIPHERAL EDEMA; PRIORITY JOURNAL; PSYCHOSIS; SIDE EFFECT; TREATMENT OUTCOME;

ADULT; AGED; ANTIPARKINSON AGENTS; DOPAMINE AGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; LEVODOPA; MALE; MIDDLE AGED; PARKINSON DISEASE; PERGOLIDE; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; TREMOR;

EID: 26444565676     PISSN: 01674943     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.archger.2005.04.002     Document Type: Article

References (30)

1. J.E. Ahlskog, and M.D. Muenter Treatment of Parkinson's disease with pergolide: a double-blind study Mayo Clin. Proc. 63 1988 969 978
2. G. Arnold Falling asleep at the wheel: motor vehicle mishaps in people taking pramipexole and ropinirole Neurology 54 2000 275 276 (author reply on pp. 276-277)
3. P. Barone, D. Bravi, F. Bermejo-Pareja, R. Marconi, J. Kulisevsky, S. Malagu, R. Weiser, and N. Rost Pergolide monotherapy in the treatment of early PD: a randomized, controlled study. Pergolide Monotherapy Study Group Neurology 53 1999 573 579
4. A.L. Benabid, P. Pollak, C. Gervason, D. Hoffmann, D.M. Gao, M. Hommel, J.E. Perret, and J. de Rougemont Long-term suppression of tremor by chronic stimulation of the ventral intermediate thalamic nucleus Lancet 337 1991 403 406
5. C.E. Clarke, and J.M. Speller Pergolide for levodopa-induced complications in Parkinson's disease Cochrane Database Syst. Rev. 2000 CD000235
6. C.E. Clarke, and J.M. Speller Pergolide versus bromocriptine for levodopa-induced motor complications in Parkinson's disease Cochrane Database Syst. Rev. 2000 CD000236
7. A. Facca, and J. Sanchez-Ramos High-dose pergolide monotherapy in the treatment of severe levodopa-induced dyskinesias Mov. Disord. 11 1996 327 329
8. S. Fahn Adverse effects of levodopa C.W. Olanow A.N. Lieberman The Scientific Basis for the Treatment of Parkinson's Disease 1992 The Parthenon Publishing Group Ltd. Park Ridge 89 112
9. J.P. Frankel, A.J. Lees, P.A. Kempster, and G.M. Stern Subcutaneous apomorphine in the treatment of Parkinson's disease J. Neurol. Neurosurg. Psychiatry 53 1990 96 101
10. S. Frucht, J.D. Rogers, P.E. Greene, M.F. Gordon, and S. Fahn Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole Neurology 52 1999 1908 1910
11. R.W. Fuller, and J.A. Clemens Pergolide: a dopamine agonist at both D1 and D2 receptors Life Sci. 49 1991 925 930
12. S. Gimenez-Roldan, E.M. Esteban, and D. Mateo Switching from bromocriptine to ropinirole in patients with advanced Parkinson's disease: open label pilot responses to three different dose-ratios Clin. Neuropharmacol. 24 2001 346 351
13. M. Gonce, and P.J. Delwaide Clinical study of pergolide in Parkinson's disease Presse Med. 14 1985 1409 1411
14. M.A. Hely, J.G.L. Morris, R.J. Burns, C.M. Lander, D.B. McLaughlin, and G.A. Donnan An Australian multicentre open label study of pergolide as an adjunct to levodopa in Parkinson's disease J. Clin. Neurosci. 3 1996 234 238
15. M.M. Hoehn, and M.D. Yahr Parkinsonism: onset, progression and mortality Neurology 17 1967 427 442
16. J. Ilson, S. Fahn, R. Mayeux, L.J. Cote, and S.R. Snider Pergolide treatment in parkinsonism Adv. Neurol. 37 1983 85 94
17. H.L. Klawans, C.M. Tanner, S. Glatt, and C.G. Goetz A 6-month trial of pergolide mesylate in the treatment of idiopathic Parkinson's disease Adv. Neurol. 37 1983 75 83
18. A.E. Lang, N. Quinn, S. Brincat, C.D. Marsden, and J.D. Parkes Pergolide in late-stage Parkinson disease Ann. Neurol. 12 1982 243 247
19. H.D. Langtry, and S.P. Clissold Pergolide. A review of its pharmacological properties and therapeutic potential in Parkinson's disease Drugs 39 1990 491 506
20. A.N. Lieberman, A. Neophytides, M. Leibowitz, G. Gopinathan, V. Pact, R. Walker, A. Goodgold, and M. Goldstein Comparative efficacy of pergolide and bromocriptine in patients with advanced Parkinson's disease Adv. Neurol. 37 1983 95 108
21. Y. Mizuno, T. Kondo, and H. Narabayashi Pergolide in the treatment of Parkinson's disease Neurology 45 1995 S13 S21
22. W.H. Oertel, J. Schwarz, K.L. Leenders, H.P. Hundemer, A. Lledo, and E.C. Wolters Results of a 3 year randomized, double blind, PET-controlled study of pergolide vs. l-dopa as monotherapy in early Parkinson's disease (PELMOPET-trial) J. Neural Transm. 187 Suppl. 2001 S444
23. C.W. Olanow, S. Fahn, M. Muenter, H. Klawans, H. Hurtig, M. Stern, I. Shoulson, R. Kurlan, J.D. Grimes, and J. Jankovic A multicenter double-blind placebo-controlled trial of pergolide as an adjunct to Sinemet in Parkinson's disease Mov. Disord. 9 1994 40 47
24. K.A. Reardon, M. Shiff, and P.A. Kempster Evolution of motor fluctuations in Parkinson's disease: a longitudinal study over 6 years Mov. Disord. 14 1999 605 611
25. U.K. Rinne, F. Bracco, C. Chouza, E. Dupont, O. Gershanik, J.F. Marti Masso, J.L. Montastruc, and C.D. Marsden Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications. Results of a double-blind levodopa controlled trial. The PKDS009 Study Group Drugs 55 Suppl. 1 1998 23 30
26. J. Schwarz, K. Scheidtmann, and C. Trenkwalder Improvement of motor fluctuations in patients with Parkinson's disease following treatment with high doses of pergolide and cessation of levodopa Eur. Neurol. 37 1997 236 238
27. S. Shaunak, A. Wilkins, J.B. Pilling, and D.J. Dick Pericardial, retroperitoneal, and pleural fibrosis induced by pergolide J. Neurol. Neurosurg. Psychiatry 66 1999 79 81
28. C.M. Tanner, C.G. Goetz, R.H. Glantz, S.L. Glatt, and H.L. Klawans Pergolide mesylate and idiopathic Parkinson disease Neurology 32 1982 1175 1179
29. C. Thalamas, I. Rajman, A. Mackie, M.P. Bareille, C. Soubrouillard, J. Kulisevsky, S. Descombes, C. Brefel-Courbon, N. Fabre, M.J. Barbanoj, O. Blin, and O. Rascol Pergolide pharmacokinetics in patients with Parkinson's disease Parkinsonism Relat. Disord. 7 Suppl. 2001 S71 S72
30. C. Trenkwalder, J. Winkelmann, H.P. Hundemer, C. Oehlwein, A. Storch, U. Polzer, and J. Schwarz High-dose treatment of Parkinson's disease with pergolide Mov. Disord. 15 Suppl. 3 2000 132 133